Lyell Immunopharma

Update in progress

LYEL (NasdaqGS)

Lyell Immunopharma is a clinical-stage cell therapy company developing CAR T-cell products for hematologic cancers and solid tumors. Its lead candidate, rondecabtagene autoleucel, is an autologous CD19/CD20 CAR T in Phase 3 and Phase 1/2 trials for large B-cell lymphoma. LYL273 is a GCC-targeted CAR T in Phase 1 for refractory metastatic colorectal cancer. Lyell uses strategies to reduce exhaustion and enhance persistence; founded in 2018 in South San Francisco.